Management of toxic epidermal necrolysis and related syndromes

被引：26

作者：

Mukasa, Y. ^{[1
]}

Craven, N. ^{[1
]}

机构：

[1] Macclesfield Hosp, Dept Dermatol, Macclesfield, Cheshire, England

来源：

POSTGRADUATE MEDICAL JOURNAL | 2008年 / 84卷 / 988期

关键词：

D O I：

10.1136/pgmj.2007.061465

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Toxic epidermal necrolysis and Stevens-Johnson syndrome are rare and life-threatening diseases that often configure as medical emergencies. The majority of cases are drug reactions. The clinical picture is one of widespread epidermal necrosis and mucosal erosions. Treatment is largely supportive and must be provided in an appropriate environment. The role of steroids and other potential disease-modifying therapies has yet to be fully established by controlled studies. The significant mortality associated with these conditions dictates that an understanding of these conditions is essential for all doctors.

引用

页码：60 / 65

页数：6

共 41 条

[31] SEVERE ADVERSE CUTANEOUS REACTIONS TO DRUGS [J].

ROUJEAU, JC ;

STERN, RS .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (19) :1272-1285

[32] TOXIC EPIDERMAL NECROLYSIS (LYELL SYNDROME) [J].

ROUJEAU, JC ;

CHOSIDOW, O ;

SAIAG, P ;

GUILLAUME, JC .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 23 (06) :1039-1058

[33] MEDICATION USE AND THE RISK OF STEVENS-JOHNSON SYNDROME OR TOXIC EPIDERMAL NECROLYSIS [J].

ROUJEAU, JC ;

KELLY, JP ;

NALDI, L ;

RZANY, B ;

STERN, RS ;

ANDERSON, T ;

AUQUIER, A ;

BASTUJIGARIN, S ;

CORREIA, O ;

LOCATI, F ;

MOCKENHAUPT, M ;

PAOLETTI, C ;

SHAPIRO, S ;

SHEAR, N ;

SCHOPF, E ;

KAUFMAN, DW .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1600-1607

[34] INCIDENCE OF STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME IN GERMANY [J].

RZANY, B ;

MOCKENHAUPT, M ;

STOCKER, U ;

HAMOUDA, O ;

SCHOPF, E .

ARCHIVES OF DERMATOLOGY, 1993, 129 (08) :1059-1059

[35] DRUG-INDUCED TOXIC EPIDERMAL NECROLYSIS (LYELL SYNDROME) IN PATIENTS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS [J].

SAIAG, P ;

CAUMES, E ;

CHOSIDOW, O ;

REVUZ, J ;

ROUJEAU, JC .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1992, 26 (04) :567-574

[36] TOXIC EPIDERMAL NECROLYSIS AND SYSTEMIC CORTICOSTEROIDS [J].

STABLES, GI ;

LEVER, RS .

BRITISH JOURNAL OF DERMATOLOGY, 1993, 128 (03) :357-357

[37] Soluble FAS ligand: A discriminating feature between drug-induced skin eruptions and viral exanthemas [J].

Stur, Karoline ;

Karlhofer, Franz M. ;

Stingl, Georg .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (04) :802-807

[38] Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin [J].

Viard, I ;

Wehrli, P ;

Bullani, R ;

Schneider, P ;

Holler, N ;

Salomon, D ;

Hunziker, T ;

Saurat, JH ;

Tschopp, J ;

French, LE .

SCIENCE, 1998, 282 (5388) :490-493

[39] Death receptors in cutaneous biology and disease [J].

Wehrli, P ;

Viard, I ;

Bullani, R ;

Tschopp, J ;

French, LE .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (02) :141-148

[40] Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis [J].

Wolkenstein, P ;

Latarjet, J ;

Roujeau, JC ;

Duguet, C ;

Boudeau, S ;

Vaillant, L ;

Maignan, M ;

Schuhmacher, MH ;

Milpied, B ;

Pilorget, A ;

Bocquet, H ;

Brun-Buisson, C ;

Revuz, J .

LANCET, 1998, 352 (9140) :1586-1589

← 1 2 3 4 5 →